Therapeutic Solutions International, Inc. (TSOI) est une société cotée en bourse dans le Santé secteur, opérant dans le Biotechnologie secteur d'activité. Le siège social de l'entreprise est situé à Elk City, ID, United States. Le PDG actuel est Timothy George Dixon.
TSOI a date d'introduction en bourse 2008-06-24, 3 employés à temps plein, cotée sur le Other OTC, une capitalisation boursière de $512.27K.
Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, traumatic brain injury, and lung pathologies, as well as for daily health. Its flagship products include QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and healthy cytokine production. The company also produces nutraceuticals, including ProJuvenol, a synergistic blend of complex anti-aging ingredients in capsules; NanoStilbene, a nanoemulsion of nanoparticle pterostilbene; DermalStilbene, a topical form of pterostilbene delivered through spray application onto skin; IsoStilbene, an injectable formulation of pterostilbene; NeuroStilbene, an intranasal form of pterostilbene; NanoPlus, a blend of NanoStilbene and Nano Cannabidiol; Nano Cannabidiol, a nanoparticle formulation of cannabidiol; NanoPSA, a blend of NanoStilbene and broccoli sprout extract; and NLRP3 Trifecta, a two-product combo that consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract. It is also developing therapeutics in chronic traumatic encephalopathy, and traumatic brain injury and lung pathology. Therapeutic Solutions International, Inc. was founded in 2007 and is based in Elk City, Idaho.
